Aristides Capital LLC Purchases New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT)

Aristides Capital LLC acquired a new position in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 156,507 shares of the company’s stock, valued at approximately $134,000. Aristides Capital LLC owned about 0.13% of Applied Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of APLT. Private Advisor Group LLC purchased a new position in shares of Applied Therapeutics during the fourth quarter worth about $35,000. SG Americas Securities LLC lifted its position in Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock worth $35,000 after acquiring an additional 25,601 shares during the period. Intech Investment Management LLC grew its stake in shares of Applied Therapeutics by 176.1% in the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock valued at $45,000 after purchasing an additional 33,567 shares during the last quarter. Swiss National Bank purchased a new position in shares of Applied Therapeutics in the 4th quarter valued at approximately $126,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Applied Therapeutics in the third quarter valued at approximately $149,000. 98.31% of the stock is currently owned by institutional investors and hedge funds.

Applied Therapeutics Price Performance

Applied Therapeutics stock opened at $0.41 on Tuesday. The stock’s 50 day moving average price is $0.54 and its 200 day moving average price is $3.58. The company has a market cap of $47.71 million, a PE ratio of -0.25 and a beta of 1.88. Applied Therapeutics, Inc. has a 1-year low of $0.36 and a 1-year high of $10.62.

Analyst Ratings Changes

Several equities research analysts recently weighed in on APLT shares. Royal Bank of Canada decreased their price target on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a report on Friday, December 20th. William Blair downgraded shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 23rd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.